A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
Type II DNA topoisomerase (topo II) is an essential nuclear enzyme and a well-validated anticancer drug target. Previously, we have carried out several rounds of structural optimizations on our in-house topo II inhibitor <b>E17</b>, which was shown to have superior anticancer activity an...
Guardado en:
Autores principales: | Zhi-Ying Li, Guang-Sen Xu, Xun Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e86a3e708ab4408d953393fc9792cecd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Assesment of the TEI index of myocardial performance in dogs with doxorubicin-induced cardiomiopathy
por: Sousa,MG, et al.
Publicado: (2014) -
Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity
por: Gao L, et al.
Publicado: (2021) -
Discovering Doris Lessing
por: Md. Mahmudul Hasan
Publicado: (2016) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
por: M. Yu. Sinitsky, et al.
Publicado: (2021) -
Nefrectomía simple por puerto único (LESS) asistida por robot (da Vinci)
por: CASTILLO C,OCTAVIO A, et al.
Publicado: (2011)